Infilea

Clobetasol Propionate, the active ingredient in Infilea, is a high‑potency topical corticosteroid presented as a topical formulation for skin use. It is prescribed for inflammatory dermatoses such as psoriasis, eczema and other forms of dermatitis in adult patients. GNH USA supplies Infilea as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Infilea is a high‑potency corticosteroid used to manage inflammatory skin disorders. - Psoriasis: reduces plaque thickness and scaling by suppressing local inflammation. - Eczema: alleviates itching and erythema through anti‑inflammatory action. - Dermatitis: controls flare‑ups and limits skin irritation by inhibiting immune responses.

Topical clobetasol may cause local and systemic reactions, most of which are dose‑related.

Common Side Effects: - Skin atrophy: thinning of the epidermis with prolonged use. - Telangiectasia: visible small blood vessels on treated areas. - Burning or stinging sensation at the application site. - Pruritus: mild itching after application.

Serious or Rare Side Effects: - Hypothalamic‑pituitary‑adrenal (HPA) axis suppression. - Secondary infection: bacterial, fungal or viral skin infections. - Allergic contact dermatitis: rash or swelling due to hypersensitivity.

Before using Infilea, consider the following safety measures. - Duration of therapy: limit continuous use to the shortest period necessary to achieve clinical response. - Application area: avoid large surface areas or occlusive dressings unless directed by a clinician. - Pre‑existing infections: treat any bacterial, fungal or viral skin infection before initiating therapy. - Pediatric use: exercise caution in children; monitor for growth‑related side effects. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Clobetasol propionate can interact with other agents that affect skin integrity or systemic corticosteroid levels.

Major Interactions (Avoid):\n- Systemic corticosteroids: concurrent use may increase risk of HPA‑axis suppression. - Potent CYP3A4 inhibitors applied to the same area: may elevate local steroid concentration.

Moderate Interactions (Monitor Closely): - Antifungal or antibacterial topicals: may reduce efficacy of either product. - Skin‑lightening agents (e.g., hydroquinone): increased irritation risk.